ICRF-159 (razoxane) in patients with advanced squamous cell carcinoma of the uterine cervix. For the Gynecologic Oncology Group.
Am J Clin Oncol
; 7(2): 131-3, 1984 Apr.
Article
en En
| MEDLINE
| ID: mdl-6702716
Thirty-one patients with advanced squamous cell carcinoma of the cervix were entered onto this phase II study evaluating the efficacy of ICRF-159 (razoxane). Three of these patients were excluded; one had no tumor, one had a second primary, and one received no therapy. ICRF-159 was administered orally at a dose of 2.5 g/m2 weekly until progression, unacceptable toxicity, or death. Adverse effects were primarily hematologic in nature. Twenty-three of the 28 patients exhibited leukopenia which in ten instances was severe (below 2000/mm3). Seven cases had thrombocytopenia (one case below 50,000/mm3). Other toxicity, including fever and anorexia, was mild to moderate. There was tumor response in five (18%) patients (one CR, four PRs) ranging from 1 to 5 months. Fifteen patients with stable disease and eight with progressive disease had a median survival duration of 3.8+ and 3.5+ months, respectively. ICRF-159 showed limited activity in this patient population. However, it might be considered for combination with other low myelosuppressive agents.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Piperazinas
/
Razoxano
/
Carcinoma de Células Escamosas
/
Neoplasias del Cuello Uterino
Límite:
Female
/
Humans
Idioma:
En
Revista:
Am J Clin Oncol
Año:
1984
Tipo del documento:
Article
Pais de publicación:
Estados Unidos